Marker SFRP1 SFRP2 SFRP5 DKK3 WIF1 APC CDH1 Unmethylated Methylated A

Slides:

Advertisements

Similar presentations

Supplementary Figure 2: Representative Kaplan-Meier plots of overall survival considering alterations erbB signaling pathway genes and p53 in lung cancer.

Advertisements

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Presented By Michael Lee at 2016 ASCO Annual Meeting

Oncol Res Treat 2016;39: DOI: /

P2X 7 Receptor and APOE Polymorphisms and Survival from Heart Failure: A Prospective Study in Frail Patients in a Geriatric Unit Giuseppe Pasqualetti;Marta.

Supporting Information for Meta-analysis

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

WT G>A G>C G>T (n = 93) (n = 21) (n = 10) (n = 51)

Nat. Rev. Urol. doi: /nrurol

Negative Thyroid Transcription Factor 1 Expression Defines an Unfavorable Subgroup of Lung Adenocarcinomas Yiliang Zhang, MD, Rui Wang, MD, PhD, Yuan.

by Michael F. Leahy, and J. Harvey Turner

Volume 74, Issue 2, Pages (August 2018)

Kaplan–Meier curves for a, b) progression-free survival (PFS) and c, d) overall survival (OS) in a, c) large-cell neuroendocrine carcinoma patients and.

EGFR Molecular Profiling in Advanced NSCLC: A Prospective Phase II Study in Molecularly/Clinically Selected Patients Pretreated with Chemotherapy Michele.

Kaplan–Meier curves of epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) progression-free survival (PFS) were constructed based on.

Programmed Cell Death Ligand 1 Expression in Resected Lung Adenocarcinomas: Association with Immune Microenvironment Tiffany G. Huynh, BA, Vicente Morales-Oyarvide,

Megan B. Barnet, BS, M. B. B. S. , Sandra O’Toole, PhD, Lisa G

Table 2. Progression-Free Survival

EML4-ALK Translocation Predicts Better Outcome in Lung Adenocarcinoma Patients with Wild-Type EGFR Shang-Gin Wu, MD, Yao-Wen Kuo, MD, Yih-Leong Chang,

Epithelial-Specific Methylation Marker: A Potential Plasma Biomarker in Advanced Non- small Cell Lung Cancer Chanida Vinayanuwattikun, MD, Virote Sriuranpong,

Karin J. C. Sanders, MD, Lizza E. Hendriks, MD, Esther G. C

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves for overall survival (OS) probability.

A Randomized Phase 2 Study Comparing the Combination of Ficlatuzumab and Gefitinib with Gefitinib Alone in Asian Patients with Advanced Stage Pulmonary.

Efficacy of Pemetrexed-Based Chemotherapy in Patients with ROS1 Fusion–Positive Lung Adenocarcinoma Compared with in Patients Harboring Other Driver Mutations.

Volume 7, Issue 11, (November 2010)

Erik Jakobsen, Maria Iachina, Karen Ege Olsen, Anders Green

miR-210 Is a Prognostic Marker in Clear Cell Renal Cell Carcinoma

Impact on Disease-Free Survival of Adjuvant Erlotinib or Gefitinib in Patients with Resected Lung Adenocarcinomas that Harbor EGFR Mutations Yelena Y.

(A) Survival time. (A) Survival time. All patients. (a) PFS since the start of EGFR-TKI (groups A, B and C). (b) OS since the start of EGFR-TKI (groups.

Jessica J. Lin, MD, Stephanie Cardarella, MD, Christine A

Perineural invasion (PNI) in vulvar carcinoma: A review of 421 cases

Phase-I/II Study of Bortezomib in Combination with Carboplatin and Bevacizumab as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer

Icotinib in Patients with Pretreated Advanced Esophageal Squamous Cell Carcinoma with EGFR Overexpression or EGFR Gene Amplification: A Single-Arm, Multicenter.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

Phase II Randomized Trial of Erlotinib or Vinorelbine in Chemonaive, Advanced, Non- small Cell Lung Cancer Patients Aged 70 Years or Older Yuh-Min Chen,

Prognostic and Predictive Markers of Benefit from Adjuvant Chemotherapy in Early- Stage Non-small Cell Lung Cancer Ana Belén Custodio, MD, José Luis González-Larriba,

EGFR Mutations Detected in Plasma Are Associated with Patient Outcomes in Erlotinib Plus Docetaxel-Treated Non-small Cell Lung Cancer Philip C. Mack,

Phase II Study of the Histone Deacetylase Inhibitor Romidepsin in Relapsed Small Cell Lung Cancer (Cancer and Leukemia Group B 30304) Gregory A. Otterson,

Nat. Rev. Urol. doi: /nrurol

Impact of Non–Small-Cell Lung Cancer-Not Otherwise Specified Immunophenotyping on Treatment Outcome Luisella Righi, MD, PhD, Tiziana Vavalà, MD, Ida.

Kaplan-Meier curves of OS by dose of nivolumab for (A) all patients (n=47), (B) PD-L1-positive patients (n=13) and (C) PD-L1-negative or unknown patients.

Early Immune-Related Adverse Events and Association with Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Michael Hsie, MD, Stefania Morbidini-Gaffney, MD, Leslie J

Figure 2 Kaplan-Meier survival graphs for 10-year risks of overall and post-90-day recurrent ischemic stroke (IS) and death Kaplan-Meier survival graphs.

A Phase II Study of Carboplatin, Etoposide, and Exisulind in Patients with Extensive Small Cell Lung Cancer: CALGB 30104 Ramaswamy Govindan, MD, Xiaofei.

Impact of Tumor Size on Local Control and Pneumonitis After Stereotactic Body Radiation Therapy for Lung Tumors Sean M. Parker, BS, R. Alfredo Siochi,

Supplementary Figure 4. Kaplan-Meier curves of 12-month readmission free survival rates according to renal dysfunction with subclassification in all (A),

Figure 3. Survival rates according to renal dysfunction

Bcl-2-Like Protein 11 Deletion Polymorphism Predicts Survival in Advanced Non–Small- Cell Lung Cancer Jih-Hsiang Lee, MD, Yu-Lin Lin, MD, Wei-Hsun Hsu,

Fig. 1. Kaplan-Meier curves for PFS and OS

Volume 9, Issue 5, Pages (November 2011)

Prognostic implication of aberrant promoter hypermethylation of CpG islands in adenocarcinoma of the lung Young Tae Kim, MD, PhD, Sun Jung Park, MS,

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Kaplan-Meier plot presenting PFS for patients with BRAFV600-mutated ctDNA at first visit (

Efficacy of nivolumab in Japanese patients with advanced non-squamous non-small cell lung cancer (A) Kaplan-Meier curve for PFS, (B) Kaplan-Meier curve.

Kaplan-Meier curves for PFS (panel A) and OS (panel B) of patients with mTCC receiving an anti-EGFR based therapy. mTCC, metastatic transverse colon cancer;

Treatment Outcomes by Tumor Histology in Eastern Cooperative Group Study E4599 of Bevacizumab with Paclitaxel/Carboplatin for Advanced Non-small Cell.

Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier plots. Progression-free (a) and overall (b) survival by age subgroup, Kaplan-Meier.

Kaplan-Meier survival analysis of p53 mutation in the overall breast tumor series. Kaplan-Meier survival analysis of p53 mutation in the overall breast.

Kaplan–Meier curve for progression-free survival for non-Asian patients with epidermal growth factor receptor (EGFR) mutation-positive status in the INTEREST.

Fig. 2. Kaplan-Meier plots for PFS and OS of 37 patients according to histological diagnosis (A and D), the extent of tumor resection (B and E), and adjuvant.

* OS >3yr with No Next Line * * * * *

Kaplan-Meier (K-M) curves of progression-free survival (PFS) of the entire cohort of patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier.

Kaplan-Meier (K-M) curves of progression-free survival (PFS) in 54 patients with metastatic gastric cancer treated with RAD001. Kaplan-Meier (K-M) curves.

Kristin A. Higgins, MD, Junzo P. Chino, MD, Neal Ready, MD, Mark W

Presentation transcript:

Figure S1 Methylated and unmethyalted bands of Wnt antagonist genes and wild/mutant EGFR Marker SFRP1 SFRP2 SFRP5 DKK3 WIF1 APC CDH1 Unmethylated Methylated A B C D S1: The example graphs of methylated and unmethyalted bands of Wnt antagonist genes (A) and EGFR wild (B) and mutation types (C, D) by methylation specific PCR and DHPLC respectively

Figure S2 PFS with different epigenotypes of Wnt antagonist genes B C SFRP1 unmethylated SFRP1 methylated SFRP2 unmethylated SFRP2 methylated D E F APC unmethylated APC methylated CDH1 unmethylated CDH1 methylated DKK3 unmethylated DKK3 methylated No methylated Any methylated Figure2S A-F.Kaplan-Meier curves of comparing the progression free survival of patients with different epigenotypes of SFRP1(A), SFRP2 (B), DKK3 (C), APC (D), CDH1 (E) and combination analysis (F).

Figure S3 OS with different epigenotypes of Wnt antagonist genes B C SFRP1 unmethylated SFRP1 methylated SFRP2 unmethylated SFRP2 methylated D E F APC unmethylated APC methylated CDH1 unmethylated CDH1 methylated DKK3 unmethylated DKK3 methylated No methylated Any methylated Figure3S A-F.Kaplan-Meier curves of comparing the overall survival of patients with different epigenotypes of SFRP1, SFRP2, DKK3, APC, CDH1 and combination analysis. Figure3S A-F. Kaplan-Meier curves of comparing the overall survival of patients with different epigenotypes of SFRP1 (A), SFRP2 (B), DKK3 (C), APC (D), CDH1 (E) and combination analysis (F).